Michael Waring
www.ncl.ac.uk
0000-0002-9110-8783
Newcastle University
72 papers found
Refreshing results…
Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α- but not β-inhibit the phosphatidylinositol signaling cascade and cancer cell proliferation
Matched triplicate design sets in the optimisation of glucokinase activators – maximising medicinal chemistry information content
Phosphatidylinositol-4-kinase-Potent and selective inhibitors of PI4K$α$ and PI4K$β$.
Optimising pharmacokinetics of glucokinase activators with matched triplicate design sets – the discovery of AZD3651 and AZD9485
Property-Based Design in the Optimisation of Benzamide Glucokinase Activators
Property-based design in the optimisation of benzamide glucokinase activators: from hit to clinic
Optimisation of biphenyl acetic acid inhibitors of diacylglycerol acetyl transferase 1 - The discovery of AZD2353
The discovery of a novel series of glucokinase activators based on a pyrazolopyrimidine scaffold
Chemical compounds 785
Benzamide derivatives useful as histone deacetylase inhibitors
Benzamide compounds useful as histone deacetylase inhibitors
Substituted pyrazines as DGAT-1 inhibitors
Therapeutic agents
Property based optimisation of glucokinase activators – discovery of the phase IIb clinical candidate AZD1656
Room-Temperature Palladium-Catalyzed Coupling of Heteroaryl Amines with Aryl or Heteroaryl Bromides
Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
Benzamide compounds
Overcoming retinoic acid receptor-α based testicular toxicity in the optimisation of glucokinase activators
Missing publications? Search for publications with a matching author name.